Ipamorelin: What the Research Shows About a Selective GH Secretagogue

What is ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide that makes the pituitary gland release a pulse of growth hormone (GH). It belongs to a class called growth hormone secretagogues: molecules that do not supply growth hormone themselves but push the body to secrete its own.

The compound came out of a medicinal-chemistry program at Novo Nordisk in the 1990s. Researchers were working through analogs of the older growth hormone-releasing peptides, and ipamorelin (internal code NNC 26-0161) emerged as the standout. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, was described by Karl Raun and colleagues in a 1998 paper in the European Journal of Endocrinology titled, plainly, "Ipamorelin, the first selective growth hormone secretagogue" (PubMed 9849822).

That title is the whole story in five words. Earlier secretagogues released growth hormone but dragged other hormones up with them. Ipamorelin was the first that behaved cleanly. It is worth being precise about what it is and is not: it is not human growth hormone, it is not an anabolic steroid, and it is not an approved medicine. It is a laboratory peptide that had a promising early profile and never crossed the finish line into clinical use.

How does ipamorelin work?

Growth hormone release from the pituitary is controlled by two opposing hypothalamic signals plus a third, appetite-linked one. Growth hormone-releasing hormone (GHRH) turns secretion on. Somatostatin turns it off. And ghrelin, the hormone best known for driving hunger, amplifies GH release through its own dedicated receptor. That receptor is formally called the growth hormone secretagogue receptor, or GHS-R1a. Ghrelin's role in the GH and appetite axis is reviewed among the peptide hormones characterized in recent decades (PubMed 34067710).

Ipamorelin is a synthetic agonist at that ghrelin receptor. When it binds GHS-R1a on the pituitary's somatotroph cells and in the hypothalamus, it mimics the amplifying signal ghrelin would normally send, and the pituitary responds with a burst of growth hormone. The original characterization confirmed the mechanism directly: using GHRH and secretagogue-receptor antagonists, Raun's team showed ipamorelin works through the same secretagogue pathway as the growth hormone-releasing peptides, not through the GHRH receptor (PubMed 9849822).

Two features follow from this. First, ipamorelin depends on a working pituitary; it cannot manufacture growth hormone where the gland cannot. Second, because it rides the body's own pulsatile machinery, it produces a spike-and-fall pattern that looks more like natural secretion than a flat, continuous level of injected hormone. Whether that pattern translates into any clinical advantage in humans has never been demonstrated.

Why ipamorelin's selectivity mattered

The reason ipamorelin is still discussed nearly three decades later comes down to what it did not do. The growth hormone-releasing peptides that preceded it, GHRP-6 and GHRP-2, were effective at raising GH but also pushed up adrenocorticotropic hormone (ACTH) and cortisol, and could nudge prolactin. For a drug you might give long-term, a built-in cortisol bump is a serious liability.

In pigs, ipamorelin released growth hormone with a potency and efficacy comparable to GHRP-6, but it did something the others could not. It left ACTH and cortisol essentially untouched, even at doses more than 200 times higher than the amount needed to release GH. It also did not disturb the reproductive or thyroid hormones FSH, LH, prolactin, or TSH (PubMed 9849822). In the authors' framing, ipamorelin was the first secretagogue-receptor agonist with a selectivity for GH release similar to GHRH itself.

That clean profile is the foundation of every claim made about ipamorelin today. It is genuinely notable pharmacology. It is also, on its own, a preclinical result in animals, and the leap from "selective in swine" to "safe and effective for people over months of use" is exactly the leap that formal drug development is supposed to test and that ipamorelin never completed. A 2020 review of growth hormone secretagogues in clinical practice makes the same point across the whole class: the pharmacology is interesting, but disciplined human evidence for the newer agents is thin (PubMed 32257855).

Does ipamorelin actually work?

Split the question, because it has two very different answers.

Does ipamorelin raise growth hormone? Yes, and this part is well established. Across primary rat pituitary cells, anesthetized rats, and conscious swine, ipamorelin produced a reliable, dose-dependent GH pulse (PubMed 9849822). Animal work has also traced that GH signal to downstream effects on bone. In adult female rats, ipamorelin and GHRP-6 increased bone mineral content over 12 weeks (PubMed 10828840), and in a separate model ipamorelin counteracted the drop in bone formation and muscle strength caused by glucocorticoid treatment (PubMed 11735244). These are legitimate, mechanistically sensible findings in animals.

Does ipamorelin produce a clinical benefit in people? Here the record is short and, frankly, disappointing for its advocates. The single most informative human study is a phase 2, randomized, double-blind, placebo-controlled trial that tested ipamorelin for postoperative ileus, the sluggish return of gut function after abdominal surgery, in bowel-resection patients. Ghrelin-receptor agonists speed gut motility, so the rationale was reasonable. In 114 analyzed patients, the median time to tolerate a solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a numerical edge that did not reach statistical significance (p = 0.15), and the authors reported no significant differences on the key or secondary endpoints (PubMed 25331030).

That is the crux. The one place ipamorelin was put to a proper controlled test in humans, it did not beat a placebo. It was well tolerated, which matters, but tolerability without efficacy is not a drug. None of the body-composition, anti-aging, or recovery claims attached to ipamorelin online rest on a controlled human trial, because those trials were never run.

Why ipamorelin is paired with CJC-1295 and GHRH analogs

Search for ipamorelin and you will almost always find it bundled with CJC-1295. There is a real physiological logic to the pairing, and it is worth understanding rather than dismissing.

Ipamorelin and CJC-1295 hit two different receptors. Ipamorelin activates the ghrelin/secretagogue receptor. CJC-1295 is a long-acting GHRH analog that activates the GHRH receptor. The pituitary integrates both inputs, and when both pathways are stimulated at once, the growth hormone response is larger than the sum of either alone, because the ghrelin-side signal also blunts somatostatin's braking effect. Combining a GHRH signal with a secretagogue signal is a classic way to amplify a GH pulse, and the two-receptor rationale is standard in the secretagogue literature (PubMed 32257855).

CJC-1295 has its own pharmacology story. The version with a drug affinity complex binds albumin and extends the GH and IGF-1 elevation for days after a single dose (PubMed 16352683). It is also worth noting a cautionary chapter in that history: CJC-1295 was later identified in an anti-doping context after a reported adverse event, underscoring that these are not clean consumer supplements (PubMed 21204297).

Two things must stay in view. First, the synergy is demonstrated at the level of hormone release, not at the level of proven health outcomes in humans. Second, pairing two unapproved research peptides does not turn them into an approved therapy. The GHRH side of that pair does have approved cousins, which is exactly what the comparison table below lays out: sermorelin and tesamorelin are GHRH analogs with real regulatory histories, while ipamorelin and CJC-1295 have none.

Is ipamorelin FDA approved?

No. Ipamorelin has never been approved by the US Food and Drug Administration, the European Medicines Agency, or any other national regulator, for any indication. There is no branded ipamorelin drug product on any market.

This is not because the molecule was never tried. As the postoperative ileus trial shows, ipamorelin did enter human testing and reached a phase 2 study before that program stalled without a positive efficacy result (PubMed 25331030). Drug development is a filter, and ipamorelin is a compound that entered the filter and did not come out the other side as a medicine. That is an ordinary outcome; most investigational drugs fail. What is not ordinary is a failed investigational peptide being sold years later as if the approval question were a technicality.

So when a clinic, a website, or a vendor implies ipamorelin is a legitimate GH therapy, the accurate correction is simple: it is investigational at best and unapproved everywhere. The only growth hormone-axis peptide in this family with a current FDA approval is tesamorelin, and that approval is narrow, covering excess abdominal fat in people with HIV-associated lipodystrophy (PubMed 20554713).

Is ipamorelin legal? The 503A bulk-list decision

Ipamorelin's legal status is more specific than a simple "yes or no," and 2024 sharpened it considerably.

In the United States, a peptide that has no approved drug product can sometimes still reach patients through compounding pharmacies, but only if the FDA has placed its bulk drug substance on an approved list under section 503A of the Food, Drug, and Cosmetic Act. Ipamorelin had been sitting in a holding category (Category 2) on the interim 503A bulks list, essentially a pending pile flagged with unresolved safety questions. In 2024 it was removed from that category, and the FDA's Pharmacy Compounding Advisory Committee reviewed ipamorelin and declined to recommend adding it to the approved list.

The practical result: as of 2024 to 2025, ipamorelin is not an approved drug and is not on the list of bulk substances a 503A pharmacy may lawfully compound. That closes the main legitimate pathway by which it had reached patients. It is not a scheduled or controlled substance, so mere possession is not a criminal matter in the way a controlled drug would be, but marketing or selling it for human use is not lawful. This is why almost everything sold online carries a "research use only, not for human consumption" label, a disclaimer that describes the true regulatory status rather than a marketing formality. Our overview of peptide legality and regulatory status explains how this compounding framework plays out across the wider peptide market.

Ipamorelin side effects reported in research

Ipamorelin's reputation for tolerability is one of its genuine strengths, and the postoperative ileus trial supports it: over up to seven days of twice-daily intravenous dosing, treatment-emergent adverse events were actually slightly less common in the ipamorelin group than in the placebo group (PubMed 25331030). The short-term, low-dose safety signal is reassuring as far as it goes.

The commonly reported effects, drawn from that trial and from clinical use of secretagogues generally, are mild: headache, facial flushing or a warm sensation, lightheadedness, and reactions at the injection site. Because ipamorelin uses the ghrelin receptor, transient hunger can occur, though the appetite effect is weaker than with less selective secretagogues.

The more important concern is not an acute side effect but a metabolic one, and it applies to anything that raises growth hormone. GH is a counter-regulatory hormone: it opposes insulin. Sustained elevation of GH can reduce insulin sensitivity and raise fasting glucose, which is a well-understood property of the entire class rather than a quirk of ipamorelin. Because there are no long-term human trials, the size of that risk with ongoing ipamorelin use is unquantified.

Two structural cautions round out an honest safety picture. First, ipamorelin sold as a research chemical is not made to pharmaceutical standards, so purity, sterility, and even identity are unverified, a hazard separate from the molecule itself and shared across the unapproved-peptide market. A 2026 review of approved and unapproved peptide therapies for musculoskeletal and athletic use, which explicitly covers ipamorelin alongside CJC-1295 and repair peptides such as BPC-157, concluded that rigorous human safety data are scarce and the potential for serious harm is real (PubMed 41966639). Second, any injected compound carries the ordinary risks of technique and contamination; see our notes on injection sites and rotation in the research literature.

Ipamorelin vs sermorelin, CJC-1295 and tesamorelin

The clearest way to place ipamorelin is against the other peptides in the growth hormone axis, sorted not by hype but by how far each got in real drug development.

The pattern is instructive. The two GHRH analogs that were carried through disciplined trials, sermorelin and tesamorelin, both earned FDA approval. Sermorelin was used to diagnose and treat growth hormone deficiency in children, with once-daily subcutaneous therapy shown to accelerate growth in deficient children (PubMed 8772599), and its clinical role is summarized in a dedicated review (PubMed 18031173). Tesamorelin reduced visceral and liver fat in HIV-infected patients across controlled trials (PubMed 20554713, PubMed 25038357). Ipamorelin, despite arguably the most elegant preclinical profile of the group, has the weakest human file. Sophistication in a dish and success in patients are not the same currency.

How long does ipamorelin take to work?

It depends entirely on what "work" means, and the honest answer separates a measurable pharmacology effect from an unmeasured cosmetic one.

The growth hormone response is fast. Secretagogues like ipamorelin produce a GH pulse within minutes of administration, peaking early and falling back toward baseline within a few hours, which is by design meant to echo a natural secretory burst (PubMed 9849822). If the question is "how quickly does ipamorelin raise GH," the answer is essentially immediately.

The changes people actually chase, shifts in body composition, recovery, or skin, would run through IGF-1 and tissue-level adaptation, which unfold over weeks to months if they occur at all. For ipamorelin specifically, none of that has been measured in a controlled human trial, so any timeline you see quoted for those outcomes is extrapolated from growth hormone biology in general, not from ipamorelin data. The bone changes seen in rats, for context, were measured over roughly 12 weeks (PubMed 10828840) — a reminder that hormonal effects on tissue are slow even when they are real.

The practical takeaway is the same one that applies to every compound with a fast biochemical signal and slow, uncertain outcomes: subjective change is easy to misattribute, and only a dated, consistent record separates a real effect from wishful thinking. That is exactly the discipline PepMate is built to support.

Frequently asked questions

Sources

Every claim above traces to peer-reviewed literature indexed on PubMed:

1. Ipamorelin, the first selective growth hormone secretagogue — PubMed 9849822
2. The role of growth hormone secretagogues in the modern clinic — PubMed 32257855
3. The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
4. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats — PubMed 10828840
5. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats — PubMed 11735244
6. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients — PubMed 25331030
7. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 — PubMed 16352683
8. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unofficial preparation — PubMed 21204297
9. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency — PubMed 18031173
10. Once daily subcutaneous growth hormone-releasing hormone therapy in GH-deficient children — PubMed 8772599
11. Effects of tesamorelin (TH9507) in HIV-infected patients with abdominal fat accumulation — PubMed 20554713
12. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients — PubMed 25038357
13. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — PubMed 41966639

Keep reading